Loading Otnox...
Otnox
USUnited States·Buyer: BARDA - ASPR / DAAPPO / BARDA DCMA

Advance the development of SCY-247, a novel antifungal currently in Phase 1 clinical trials, for the treatment of invasive candidiasis and prophylaxis of invasive fungal disease as oral and IC formula

Awarded·25 Sep 2026·USD 213,943,726

Published

25.09.2026

Awarded

25.09.2026

Otnox

Find tenders worth bidding for.

Create an account to explore this tender and find similar opportunities.

  • Tender documentsReview available files in one workspace.
  • Requirements and risksRequest a document analysis with references to the sources.
  • Your tender selectionContinue with your selected markets and sectors.